PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization

[ACN Newswire] – In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic Myeloid … more

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard